Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated indications. Pharvaris N.V. is based in ZUG, Switzerland.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-50.56M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.71 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -24.98% |
Return on Assets (Trailing 12 Months) | -24.05% |
Current Ratio (Most Recent Fiscal Quarter) | 19.84 |
Quick Ratio (Most Recent Fiscal Quarter) | 19.84 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $7.62 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.54 |
Earnings per Share (Most Recent Fiscal Year) | $-1.66 |
Diluted Earnings per Share (Trailing 12 Months) | $-2.60 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 31.84M |
Free Float | -- |
Market Capitalization | $580.76M |
Average Volume (Last 20 Days) | 7482.90 |
Beta (Past 60 Months) | -0.79 |
Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
Percentage Held By Institutions (Latest 13F Reports) | 79.32% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |